Compare HBB & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBB | TRDA |
|---|---|---|
| Founded | 1904 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.2M | 275.3M |
| IPO Year | 2017 | 2021 |
| Metric | HBB | TRDA |
|---|---|---|
| Price | $32.07 | $7.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 90.9K | ★ 247.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.75 | N/A |
| Revenue | ★ $606,852,000.00 | $25,421,000.00 |
| Revenue This Year | N/A | $39.97 |
| Revenue Next Year | N/A | $50.80 |
| P/E Ratio | $11.46 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.56 | $5.02 |
| 52 Week High | $34.26 | $16.45 |
| Indicator | HBB | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 61.42 | 49.63 |
| Support Level | $17.90 | $5.71 |
| Resistance Level | $34.19 | $7.95 |
| Average True Range (ATR) | 1.04 | 0.39 |
| MACD | -0.56 | -0.04 |
| Stochastic Oscillator | 46.96 | 37.86 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.